Peptide Reference
Cerebrolysin
Cerebrolysin
A parenteral nootropic drug consisting of low molecular weight peptides and amino acids derived from porcine brain tissue. Used clinically for stroke, TBI, and dementia treatment.
Status
approved
Category
cognitive
Typical cost
$300-600 for 4-week course
Mechanism
Provides neurotrophic support, enhances neuroplasticity, reduces neuroinflammation, and promotes neuronal survival. Contains neurotrophic factors that cross blood-brain barrier.
Potential benefits
- Cognitive enhancement
- Stroke recovery
- Dementia symptom management
- Neuroprotection
- TBI recovery
- Improved memory and focus
- TBI support
Reported side effects
- Injection site reactions
- Mild dizziness
- Headache
- Nausea (rare)
- Allergic reactions (rare)
- Dizziness
- Allergy to porcine products
Common dosing references
intramuscular
2-10ml · Daily or 3-5x weekly
4-6 weeks
intravenous
10-30ml · Daily
10-14 days
intramuscular or intravenous
10-30mL · Daily or 5x weekly
10-20 days
Research notes
Cerebrolysin in Alzheimer's disease
2013
Meta-analysis showed significant improvement in cognitive function and global clinical status
Cerebrolysin in acute ischemic stroke
2015
Improved neurological recovery when administered within 24 hours of stroke onset
Cerebrolysin stroke recovery
2005
Improved functional outcomes when started within 72 hours of stroke
Cerebrolysin Alzheimer's
2008
Slowed cognitive decline in Alzheimer's patients
Regulatory and sourcing notes
Approved in over 50 countries for dementia, stroke, and TBI. Not FDA-approved in US. Available by prescription in many countries.
Prescription in approved countries. Requires injection administration. Peptide/amino acid complex, not single peptide.
Find peptide-aware clinics
Use location pages to compare clinics with peptide therapy signals and verify clinical oversight before treatment.